Sign in

    Samantha Lynn Semenkow

    Research Analyst at Citigroup

    Samantha Lynn Semenkow is an Analyst at Citigroup Global Markets Inc., specializing in equity research across the biotechnology and pharmaceutical sectors. She covers companies including WAVE Life Sciences, Prime Medicine, Cabaletta Bio, Allogene Therapeutics, argenx, and Structure Therapeutics, making investment calls and issuing price targets for these firms. With approximately six years of experience at Citigroup, Semenkow began her financial advisory career in Getzville, NY, and has built a performance record that is tracked by independent platforms, though specific public metrics on returns or rankings remain limited. She is registered as a financial professional and operates under Citigroup's FINRA-regulated entity, indicating compliance with industry credentials and regulatory standards.

    Samantha Lynn Semenkow's questions to Immunovant (IMVT) leadership

    Samantha Lynn Semenkow's questions to Immunovant (IMVT) leadership • Q3 2024

    Question

    Samantha Lynn Semenkow asked about the heterogeneity of rheumatoid arthritis (RA) patients with high ACPA levels and the potential for IMVT-1402 to be effective as a monotherapy versus requiring combination therapy.

    Answer

    Guest speaker Dr. Peter Taylor of the University of Oxford explained that ACPA-positive RA patients are a more homogeneous group than seronegative patients. He noted that while trials are needed to confirm, data from a competitor's less potent FcRn inhibitor showed strong responses with monotherapy, suggesting a more potent drug like IMVT-1402 has significant potential for providing clinically meaningful benefits alone.

    Ask Fintool Equity Research AI

    Samantha Lynn Semenkow's questions to Immunovant (IMVT) leadership • Q3 2024

    Question

    Samantha Lynn Semenkow of Citigroup inquired about the heterogeneity of rheumatoid arthritis (RA) patients with high ACPA levels and whether this population is more homogeneous. She also asked for thoughts on the potential effectiveness of IMVT-1402 as a monotherapy versus requiring combination therapy.

    Answer

    Guest expert Dr. Peter Taylor from the University of Oxford explained that while RA is complex, ACPA-positive patients are generally more homogeneous than seronegative patients. He noted that the rationale for targeting FcRn is supported by nipocalimab data showing strong responses with monotherapy. Dr. Taylor stated that the expectation, based on existing data and the higher IgG reduction of IMVT-1402, is that a significant proportion of patients would respond well to monotherapy.

    Ask Fintool Equity Research AI